{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:31:11Z","timestamp":1740126671864,"version":"3.37.3"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["F30HL154324"],"award-info":[{"award-number":["F30HL154324"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001855"],"award-info":[{"award-number":["UL1TR001855"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["semthorcardiovascsurg.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1053\/j.semtcvs.2022.10.005","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T04:58:55Z","timestamp":1666241935000},"page":"261-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trial"],"prefix":"10.1053","volume":"36","author":[{"given":"Omar","family":"Toubat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyue","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean C.","family":"Wightman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott M.","family":"Atay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Harano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semtcvs.2022.10.005_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"year":"2022","series-title":"Cancer Facts & Figures 2022","key":"10.1053\/j.semtcvs.2022.10.005_bib0002"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0003","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0004","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Ettinger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"5 Suppl","key":"10.1053\/j.semtcvs.2022.10.005_bib0005","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.12-2359","article-title":"Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Howington","year":"2013","journal-title":"Chest"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0006","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0007","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.athoracsur.2019.11.059","article-title":"Disparities in guideline-concordant treatment for pathologic N1 non-small cell lung cancer","volume":"109","author":"Toubat","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0008","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jtcvs.2019.10.102","article-title":"Disparities in guideline-concordant treatment for node-positive, non-small cell lung cancer following surgery","volume":"160","author":"Farrow","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0009","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jtcvs.2016.01.058","article-title":"Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?","volume":"151","author":"Bott","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaoncol.2022.0039","article-title":"Rates of guideline-concordant surgery and adjuvant chemotherapy among patients with early-stage lung cancer in the US ALCHEMIST Study (Alliance A151216)","volume":"8","author":"Kehl","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0011","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/JTO.0b013e3181c814e7","article-title":"Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation","volume":"5","author":"Douillard","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0012","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0013","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jclinepi.2012.09.017","article-title":"A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions","volume":"66","author":"Latouche","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0014","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0015","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1053\/j.semtcvs.2021.01.012","article-title":"Chemotherapy and surgical resection for N1 positive non-small cell lung cancer: better than expected outcomes","volume":"33","author":"White","year":"2021","journal-title":"Semin Thorac Cardiovasc Surg"},{"year":"2022","series-title":"Epidemiology, and End Results Program: Cancer Stat Facts Lung and Bronchus Cancer","key":"10.1053\/j.semtcvs.2022.10.005_bib0016"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0017","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.lungcan.2007.03.012","article-title":"National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care","volume":"57","author":"Little","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0018","article-title":"A risk model to predict the delivery of adjuvant chemotherapy following lung resection in patients with pathologically positive lymph nodes","author":"Patella","year":"2022","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0019","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.lungcan.2004.08.016","article-title":"Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature","volume":"47","author":"Alam","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0020","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0003-4975(99)00276-3","article-title":"Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung","volume":"67","author":"Riquet","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0021","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1010-7940(01)00670-4","article-title":"Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC)","volume":"19","author":"Tanaka","year":"2001","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0022","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.athoracsur.2008.12.053","article-title":"Prognostic significance of surgical-pathologic N1 lymph node involvement in non-small cell lung cancer","volume":"87","author":"Demir","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0023","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ejso.2014.10.003","article-title":"Prognostic factors after surgical resection of N1 non-small cell lung cancer","volume":"41","author":"Mordant","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0024","doi-asserted-by":"crossref","first-page":"21606","DOI":"10.1038\/s41598-021-01136-2","article-title":"Prognostic value of different N1 lymph node zones in pN1M0 non-small cell lung cancer: a systematic review and meta-analysis","volume":"11","author":"Hu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.athoracsur.2007.03.030","article-title":"Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer","volume":"84","author":"Cerfolio","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0026","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.jtcvs.2019.09.075","article-title":"The influence of adjuvant therapy on survival in patients with indeterminate margins following surgery for non-small cell lung cancer","volume":"159","author":"Raman","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0027","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejcts.2004.03.041","article-title":"Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial","volume":"26","author":"Waller","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0028","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/jamaoncol.2016.5829","article-title":"Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery","volume":"3","author":"Salazar","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0029","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2010.28.1709","article-title":"Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study","volume":"28","author":"Booth","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0030","first-page":"185","article-title":"Rates of guideline adherence among US community oncologists treating NSCLC","volume":"19","author":"Wang","year":"2013","journal-title":"Am J Manag Care"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0031","first-page":"243","article-title":"Adjuvant chemotherapy after resection of N1 non-small cell lung cancer: differential impact of new evidence on physician and patient decisions","volume":"7","author":"Coleman","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0032","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jtcvs.2018.09.126","article-title":"Evaluation of adherence to the Commission on Cancer lung cancer quality measures","volume":"157","author":"Odell","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0033","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/bmjqs-2019-009742","article-title":"Failure to administer recommended chemotherapy: acceptable variation or cancer care quality blind spot?","volume":"29","author":"Ellis","year":"2020","journal-title":"BMJ Qual Saf"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0034","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1053\/j.semtcvs.2022.10.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8500","article-title":"IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)","author":"Wakelee","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semtcvs.2022.10.005_bib0036","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33205","article-title":"Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies","volume":"4","author":"Aldrighetti","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Seminars in Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104306792200257X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104306792200257X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T07:13:07Z","timestamp":1716966787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104306792200257X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"alternative-id":["S104306792200257X"],"URL":"https:\/\/doi.org\/10.1053\/j.semtcvs.2022.10.005","relation":{},"ISSN":["1043-0679"],"issn-type":[{"type":"print","value":"1043-0679"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trial","name":"articletitle","label":"Article Title"},{"value":"Seminars in Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semtcvs.2022.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}